A Phase 1 interventional study of NNC0363-1063 and Placebo in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 53rd largest by enrollment of the 149 interventional ones that give a count, is one of 2 that started in 2024, is one of 74 in phase 1, and was the 218th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–55
Novo Nordisk A/S · Sites in Japan
By country, each count listing its studies:
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
226 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 40 across 2,823 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 62 across the 149 interventional studies, 1,068 across the 77 observational. Of the 220 that completed or were terminated, 33 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
3 of the studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT07160816Novo Nordisk A/SA Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar | 2027-01-20 |
| NCT06807190Novo Nordisk A/SGeneral Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 3½ to 8½ weeks. Part 3 is a meal test multiple dose study part conducted in participants with T1D and will last for 7 to 11 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1A SAD (healthy participants)
Part 1B SAD, Part 2 PoP and Part 3 Meal test (participants with T1D)
Exclusion Criteria:
Part 1A SAD (healthy participants)
Part 1B SAD, Part 2 PoP and Part 3 Meal test (participants with T1D)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of NNC0363-1063 subcutaneously.
Drug: NNC0363-1063
Participants will receive NNC0363-1063 matching placebo subcutaneously.
Drug: Placebo
Participants will receive NNC0363-1063 subcutaneously.
Drug: NNC0363-1063
Participants will receive insulin degludec subcutaneously.
Drug: Insulin degludec
Participants will receive NNC0363-1063 subcutaneously.
Drug: NNC0363-1063
Participants will receive NNC0363-1063 subcutaneously.
Drug: NNC0363-1063
Participants will receive insulin detemir subcutaneously.
Drug: Insulin detemir
NNC0363-1063 will be administered subcutaneously.
Placebo will be administered subcutaneously.
Insulin degludec will be administered subcutaneously.
Also known as: Tresiba
Insulin detemir will be administered subcutaneously.
Also known as: Levemir
Part 1 SAD: Number of adverse events
Measured in number of events.
Time frame: From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)
Part 2 PoP: CL/F,I1063,SD- Apparent serum clearance of NNC0363-1063 after a single dose
Measured in millilitre per hour\*kilogram (mL/\[h\*kg\]).
Time frame: From IMP administration at day 1 up to 7 days
Part 3 Meal test: AUC,PG,meal: Area under the plasma glucose concentration-time curve at steady state
Measured in hours\*millimoles per litre (h\*mmol/L).
Time frame: At day 2 of visit 2 and visit 3 after initiation of meal test
Part 1 SAD: Number of hypoglycaemic episodes
Measured in number of episodes.
Time frame: From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)
Part 1 SAD: AUC0-inf,I1063,SD: Area under the serum NNC0363-1063 concentration-time curve from 0 to infinity after a single dose
Measured in hours\*picomoles per litre (h\*pmol/L).
Time frame: Up to 7 days
Part 1 SAD: AUC,I1063,SD- Area under the serum NNC0363-1063 concentration time curve after a single dose
Measured in h\*pmol/L.
Time frame: Up to 2 days
Part 1 SAD: Cmax,I1063,SD- Maximum observed serum NNC0363-1063 concentration after a single dose
Measured in picomoles per litre (pmol/L).
Time frame: Up to 7 days
Part 2 PoP: AUC0-inf,I1063,SD: Area under the serum NNC0363-1063 concentration-time curve from 0 to infinity after a single dose
Measured in h\*pmol/L.
Time frame: Up to 7 days
Part 2 PoP: AUC,I1063,SD- Area under the serum NNC0363-1063 concentration time curve after a single dose
Measured in h\*pmol/L.
Time frame: Up to 2 days
Part 2 PoP: Cmax,I1063,SD- Maximum observed serum NNC0363-1063 concentration after a single dose
Measured in pmol/L.
Time frame: Up to 7 days
Part 3 Meal test: AUC0-1h,PG,meal: Area under the plasma glucose concentration-time curve from 0 to 1 hour after initiation of the meal test at steady state
Measured in h\*mmol/L.
Time frame: From 0 hours to 1 hour after initiation of the meal test (day 2 of visit 2 and visit 3)
Part 3 Meal test: AUC0-2h,PG,meal: Area under the plasma glucose concentration-time curve from 0 to 2 hours after initiation of the meal test at steady state
Measured in h\*mmol/L.
Time frame: From 0 hours to 2 hours after initiation of the meal test (day 2 of visit 2 and visit 3)
Part 3 Meal test: AUC0-4h,PG,mean: Area under the plasma glucose concentration-time curve from 0 to 4 hours after initiation of the meal test at steady state
Measured in h\*mmol/L.
Time frame: From 0 hours to 4 hours after initiation of the meal test (day 2 of visit 2 and visit 3)
Part 3 Meal test: AUC0-6h,PG,meal: Area under the plasma glucose concentration-time curve from 0 to 6 hours after initiation of the meal test at steady state
Measured in h\*mmol/L.
Time frame: From 0 hours to 6 hours after initiation of the meal test (day 2 of visit 2 and visit 3)
Part 3 Meal test: PGmax,meal: Maximum observed plasma glucose concentration at steady state
Measured in millimoles per litre (mmol/L).
Time frame: At day 2 of visit 2 and visit 3 after initiation of meal test
Part 3 Meal test: tPGmax,meal: Time to maximum observed plasma glucose concentration from at steady state
Measured in hours.
Time frame: At day 2 of visit 2 and visit 3 after initiation of meal test
Part 3 Meal test: ΔPGav,0-1h,meal: Mean change in plasma glucose from 0 to 1 hour after initiation of the meal test at steady state
Measured in mmol/L.
Time frame: From 0 hours to 1 hour after initiation of the meal test (day 2 of visit 2 and visit 3)
Part 3 Meal test: ΔPGav,0-2h,meal: Mean change in plasma glucose from 0 to 2 hours after initiation of the meal test at steady state
Measured in mmol/L.
Time frame: From 0 hours to 2 hours after initiation of the meal test (day 2 of visit 2 and visit 3)
Part 3 Meal test: AUCτ,I1063,SS: Area under the serum NNC0363-1063 concentration-time curve during one dosing interval at steady state
Measured in h\*pmol/L.
Time frame: At day 2 of visit 2 and visit 3 after last IMP administration
Part 3 Meal test: Cmax,I1063,SS: Maximum observed serum NNC0363-1063 concentration during one dosing interval at steady state
Measured in pmol/L.
Time frame: At day 2 of visit 2 and visit 3 after last IMP administration
Part 3 Meal test: Number of adverse events
Measured in number of events.
Time frame: From first IMP administration (day 1 of visit 2 and visit 3) until 24 hours after last IMP administration (day 2 of visit 2 and visit 3)
Part 3 Meal test: Number of hypoglycaemic episodes
Measured in number of episodes.
Time frame: From first IMP administration (day 1 of visit 2 and visit 3) until 24 hours after last IMP administration (day 2 of visit 2 and visit 3)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Mar 2026, 15 months.
Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 15 months is above that.
Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.